Rainbow Childrens Medicare Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Healthcare Services | Market Cap: ₹14.6K Cr
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Rainbow Children's Medicare expects continued volume growth from both matured and new hospitals, with new hospitals growing faster and adding 12.5% capacity in FY '25-'26.
From Rainbow Childrens Medicare Ltd's Q3 FY25 earnings-call transcript · updated 26 Aug 2026.
Price
₹1,445
Market Cap
₹14.6K Cr
P/E Ratio
50.8
How does Rainbow Childrens Medicare Ltd rank in Healthcare Services?
Compare Rainbow Childrens Medicare Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Rainbow Childrens Medicare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹460 Cr, net profit ₹78 Cr.
Full financials →📊 Revenue & Sales Performance
- →Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis.
- →New hospitals (operational less than 5 years) grow faster than mature hospitals, contributing to volume growth.
- →Three new hospitals are planned in FY '25-'26, adding ~250 beds (12.5% capacity expansion), and ~130 beds planned for FY '26-'27.
- →New hospitals are on expected occupancy and profitability trajectory, with breakeven expected within 12-18 months for recent openings.
- →ARPP (Average Revenue Per Patient) growth is projected at 5%-8% due to pricing power and handling more complex cases as centers mature.
- →Overall volume growth is supported by adding doctors, specialties in mature hospitals, and faster growth from newer hospitals.
- →Expansion includes new geographies such as NCR (400 beds planned), regional spokes, and cities like Rajahmundry and Coimbatore.
- →International business is in an early phase and expected to grow once macro uncertainties ease.
📈 Profitability & Margins
- →Rainbow Children's Medicare expects continued volume growth from both matured and new hospitals, with new hospitals growing faster and adding 12.5% capacity in FY '25-'26.
- →ARPP (Average Revenue per Patient) growth guidance is 5%-9% year-on-year, driven by pricing power as centers mature and handling more complex cases.
- →EBITDA margins expected to stay around 32.7%, with only minor fluctuations (+/- 1%) despite new hospital additions causing some drag initially.
- →New hospitals like Hyderabad, Bangalore, and Chennai are on track to breakeven within 12-18 months, contributing positively soon.
- →Capital expenditure planned primarily via leased assets with INR 550 crores over next 3 years, including large Gurgaon facility, which will impact ROCE temporarily but adds scale (25%-30% larger bed base).
- →Mature hospitals occupancy growth and a move towards higher occupancy levels (up to 68%-70%) support revenue growth.
- →Overall, earnings/profit growth is underpinned by a balanced expansion strategy, price adjustments, and operational efficiencies.
🏗️ Capital Expenditure Plans
- →FY '25-26: Adding ~250 beds through asset-light leased assets, with capex of approximately INR 60-65 lakh per bed.
- →FY '26-27: Plan to add ~130 beds, totaling roughly 380-400 beds over two years.
- →Gurugram Project: INR 180-190 crores spent on land and approvals; an additional INR 400 crores expected as capex over FY '25-26 to FY '27-28, mostly post one year.
- →Gurugram hospital to be a state-of-the-art, capital-intensive super-specialty facility with approx. INR 1.5 crores capex per bed.
- →Total planned capex over next 2-3 years is around INR 550 crores.
- →Capital expenditure expected to be funded via internal accruals without debt financing.
- →The company is also open to potential acquisitions to increase capacity by 25-30% by the time the Gurugram facility starts.
💰 Fundraising & Capital Structure
- →Rainbow Children's Medicare Limited currently has a strong balance sheet with a net cash position of INR 667 crores as of December 31, 2024.
- →The company remains confident in its ability to complete all planned capital expenditures through internal accruals without any debt financing.
- →No mention of any current or planned fundraising through debt or equity was made during the call.
- →Capital expenditure plans include asset-light expansions (leased assets) with an estimated capex of INR 60-65 lakh per bed.
- →The large Gurgaon hospital project will require approximately INR 400 crores over the next 3 years, but the expenditure will be mostly after one year.
- →Overall, the company suggests no need for external fundraising in the near term, relying instead on internal cash generation.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Rainbow Childrens Medicare Ltd Q3 FY25 results?
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Rainbow Children's Medicare expects continued volume growth from both matured and new hospitals, with new hospitals growing faster and adding 12.5% capacity in FY '25-'26.
What is Rainbow Childrens Medicare Ltd share price analysis?
Rainbow Childrens Medicare Ltd currently shows a neutral. The stock trades at a P/E of 50.8 with a market cap of ₹14,557 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rainbow Childrens Medicare Ltd planning capital expenditure?
FY '25-26: Adding ~250 beds through asset-light leased assets, with capex of approximately INR 60-65 lakh per bed. - FY '26-27: Plan to add ~130 beds, totaling roughly 380-400 beds over two years. - Gurugram Project: INR 180-190 crores spent on land and approvals; an additional INR 400 crores expected as capex over FY '25-26 to FY '27-28, mostly post one year. - Gurugram hospital to be a state-of-the-art, capital-intensive super-specialty facility with approx.
Keep Rainbow Childrens Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.